After a decade-long biopharma boom cycle, companies in the sector around the world are now facing a funding crunch. During the deep freeze, they can’t afford to go it alone, some investors say.
“China biotechs need to work with the US, Europe and Japanese drug makers” to develop new drugs, partner at Qiming Capital Nisa Leung said during the Hong Kong Biotech Summit, held on 1 September. The large healthcare fund has raised $9
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?